ABSTRACT
Lymphocytes express most components of the cholinergic system including acetylcholine (ACh), muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively), choline acetyltransferase (ChAT), high affinity choline transporter and acetylcholinesterase. ACh and mAChR agonists elicit intracellular Ca Phytohemagglutinin-or antigen-induced T cell activation via cell surface molecules (e.g., T cell receptor/CD3 complexes) enhances lymphocytic cholinergic transmission by up-regulating ChAT and M 5 mAChR expression. It is thus likely that a local lymphocytic cholinergic system is involved in regulating immune function. This idea is supported by the findings that lymphocytic cholinergic activity Increase of cGMP synthesis 3.
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Activation of selective nonadherent cell proliferation 10. Inhibition of PHA-induced DNA synthesis 11. Inhibition of PHA-induced INF-gamma synthesis 12. Inhibition of IgM secretion 13. Activation of IP 3 synthesis 14. Increase of [Ca 2+ ] i 15. Activation of PHA-induced IL-2 production 16. Enhancement of IL-2 receptor mRNA expression 17. Enhancement of c-fos gene expression IP 3 , inositol trisphosphate; PHA, phytohemagglutinin; IL-2, interleukin-2; IgM, immunoglobulin M; INF-gamma, interferongamma; [Ca 2+ ] intracellular free calcium ion concentration is altered in animal models exhibiting immunological abnormalities. In addition, it appears likely that during interactions mediated by cell surface molecules T cells communicate via ACh with thymic epithelial cells and vascular endothelial cells, which also express ChAT and nAChRs or mAChRs. This interaction leads to T cell selection and maturation in the thymus and local vascular smooth muscle relaxation. Collectively, these data provide a compelling picture in which lymphocytes constitute a cholinergic system that is independent of cholinergic nerves, and which is involved in the regulation of immune function and local circulation.
INTRODUCTION
Acetylcholine (ACh) is familiar to most of us as an important neurotransmitter found in the central and peripheral cholinergic nervous systems; indeed, it was the first compound ever recognized as a neurotransmitter. It is now known, however, that ACh and ACh-synthesizing activity are expressed ubiquitously among widely diverse organisms that include eubacteria, fungi, various kinds of plants, and lower animals such as sponges and nematodes, and higher animals such as insects and vertebrates (1-3). Moreover, Yamada et al. (4) recently found that several strains of archaea also express certain levels of ACh and ACh-synthesizing activity. One notable finding is that the tips of bamboo shoot (Phyllostachys bambusoides), which grow very rapidly and express ACh at a level of about 440 microg/g wet weight, which is about 80 to 100 times higher than the level in rat striatum, the region containing the highest amount of ACh in the brain (1, 5). Taken together, these findings support the notion that ACh has been expressed by organisms since origin of life and that it is locally involved in the regulation of cellular function.
Knowledge about the synthesis, storage, metabolism and actions of ACh has been derived mostly from studies of the mammalian nervous system. ACh is synthesized by choline acetyltransferase (ChAT, EC 2.3.1.6) from acetyl coenzyme A (AcCoA) and choline taken up by the high affinity choline transporter (CHT1) (6) in the central cholinergic nerves, and by ChAT and, to a lesser extent, carnitine acetyltransferase (CarAT, EC 2.3.1.7) in the periphery (7, 8) . The synthesized ACh is transported from the cytosol into synaptic vesicles by the vesicular ACh transporter (VAChT) (9). After which stored ACh is released by exocytosis mediated by a rise in the intracellular free Ca 2+ concentration ([Ca 2+ ] i ) (10). Upon release, ACh acts on either muscarinic or nicotinic ACh receptors (mAChR and nAChR, respectively) on the targets and is then rapidly hydrolyzed by acetylcholinesterase (AChE, EC 3.1.1.7) or butyrylcholinesterase, also known as cholinesterase (ChE) into choline and acetate.
It is now clear that ACh, ChAT, and various mAChRs and nAChRs subtypes are all expressed in nonneuronal mammalian tissues and organs, including lymphocytes (see reviews by Fujii and Kawashima (11) and ); mucocutaneous epithelia (see reviews by Grando (15, 16)); gastrointestinal, respiratory and urogenital epithelial cells (see reviews by The data indicating that AChRs are expressed in lymphocytes have been accumulating since the early 1970s (for review, see Kawashima & Fujii (12) ). ACh and both mAChR and nAChR agonists elicit a variety of functional and biochemical effects in lymphocytes (Table 1 ) (12). On the basis of these findings, the notion of cross-talk between the cholinergic nervous system and the immune system was postulated and accepted widely. However, considering the enzymatic and physicochemical fragility of ACh, as well as the absence of histochemical and anatomical evidence of cholinergic innervations of the immune system, one would have to conclude that it is highly unlikely that ACh released from cholinergic nerve endings interacts directly with AChRs expressed on lymphoid cells. In this review, we will discuss the evidence for the expression of a non-neuronal cholinergic system in lymphocytes, its regulatory mechanisms, possible physiological functions, and the relationship between lymphocytic cholinergic activity and immune function in immune deficiency models.
EXPRESSION OF CHOLINERGIC COMPONENTS IN LYMPHOCYTES
Lymphocytes express most cholinergic components found in the nervous system: 1. AChRs (mAChRs and nAChRs); 2. ACh; 3. ChAT; 4. VAChT; 5. CHT1 and 6. AChE. ---+  +  C E M * : T  +  -+  +  +  MOLT-3: T  --+  +  +  HPB-ALL: T  --+  +  +  H U T -7 8 : T  +  +  +  +  +  J u r k a t : T  ---+  +  D a u d i : B  -+  +  +  +  BALL-1: B  +  --+  +  N A L M -6 : B  ---+  +  M, male ; F, female; Mo, monocytes; MNLs, mononuclear leukocytes; Pro, promyelocytic leukemic cells;-, negative;+, positive. CEM*, CCRF-CEM; +a, 5 out of 10 samples
AChRs
Both mAChRs and nAChRs are expressed in lymphocytes, and expression of nAChRs has recently been detected in the thymus.
mAChRs in lymphocytes
Expression of mAChRs has been confirmed in lymphocytes prepared from blood, lymph node, spleen and thymus of mouse, rat and human using ligand binding techniques (Table 2 ) (for review, see Kawashima & Fujii (12) ). In addition, five distinct mAChR subtypes (M 1 -M 5 ), acting via two different second messenger signaling systems, have been identified by molecular cloning (28-30). The M 1 , M 3 and M 5 mAChR subtypes are coupled to G q/11 , which, upon stimulation, mediates activation of phospholipase C (PLC), leading to increases in [Ca 2+ ] i . The M 2 and M 4 mAChR subtypes are coupled to G i/o , which, upon stimulation, mediates inhibition of adenylyl cyclase, leading to declines in cAMP production (31).
Reverse transcription-polymerase chain reaction (RT-PCR), Northern blot analyses and immunocytochemical techniques using monoclonal antibodies (mAb) against specific mAChR subtypes have all been used to detect the expression of specific mAChR subtypes in lymphocytes (Table  3 ) (32-38). M 3 , M 4 and M 5 mAChRs have been identified in almost all human peripheral blood lymphocytes tested, whereas expression of M 1 and M 2 mAChRs varies among individual subjects (34). Immunohistochemical studies have shown that the M3 subtype is the most strongly expressed mAChR, followed in order by the M5, M4 and M2 subtypes (37). Which is in line with binding experiments in human mononuclear leukocytes (MNLs), showing the relative density of the mAChR subtypes T  -+  -+  +  +  --+  MOLT-3: T  -+  -+  +  ---+  HPB-ALL: T  +  --+  +  +  --+  HUT-78: T  +  --+  +  ----Jurkat: T  --------+  Daudi: B  +  --+  +  +  ---BALL-1: B  ---+  +  -+  -+  NALM-6: B  ---+  --+  -+  F, female; M, male; MNLs, mononuclear leukocytes; T, T cells; B, B cells; -, negative; +, positive; CEM*, CCRF-CEM; +a, 8 out of 10 samples; +b, 2 out of 7 samples; +b, 3 out of 7 samples to be M 3 >M 5 >M 4 >M 2 in healthy subjects (35). That expression of M 2 and, to a lesser extent, M 5 was more strongly expressed in MNLs from asthmatic patients than from healthy subjects, while expression of M 4 was unchanged (35), suggests the pattern of expression of mAChR subtypes may vary with the physiological conditions of the subject. Costa et al. (39) detected mRNAs encoding the M 3 and M 4 mAChR subtypes in rat lymphocytes. Whether the pattern of expression of mAChR subtypes in lymphocytes differs among mammalian species is not yet known.
nAChRs in lymphocytes
The expression of nAChRs in human, rabbit and rat lymphocytes and thymocytes has been demonstrated in the binding studies using labeled nicotine and alpha-bungarotoxin (alpha-BTX), and in immunocytochemical studies (40-46). nAChRs are located on the plasma membranes of skeletal muscle cells and neurons. They exist as pentamers comprised of one to four distinct subunits (from among the alpha, beta, gamma, delta and epsilon subunits) forming a ligand-gated ion channels. Upon activation by ACh or other agonists, membrane depolarization and excitation are mediated by a rapid increase in the membrane permeability to Na + , K + and Ca
2+
. From among these subunits, at least two copies of the alpha subunit are always present; multiple binding sites for ACh are formed at the interfaces of each alpha subunit and a neighboring subunit.
The heterogeneity among nAChRs was revealed by molecular cloning (30). In skeletal muscle, the so called muscle type nAChRs contain four distinct subunits within the pentameric complex: (alpha1) 2 /beta1/delta/gamma or (alpha1) 2 /beta1/delta/epsilon. nAChRs in embryonic or denervated muscle contain a gamma subunit, whereas an epsilon subunit replaces the gamma in innervated, adult muscle. By contrast, nAChRs in the central nervous system, the so called neuron type nAChRs, are comprised of only alpha and beta subunits; six alpha (alpha2-alpha7) and three beta (beta2-beta4) subtypes have been identified in the mammalian nervous system. In addition, the alpha8 subtype is expressed in the visual areas of the avian brain (47), and the alpha9 and alpha10 subtypes have been detected in the hair cells of the mammalian inner ear (48). The alpha subunits also can be subdivided according to their sensitivity to alpha-BTX: alpha1 and alpha7, perhaps also alpha8 and alpha9, are alpha-BTX-sensitive, while alpha2-alpha6 are alpha-BTX-insensitive. 
nAChRs in the thymus
Thymus tissue consists of thymocytes (lymphoid cells) and thymic stromal cells (non-lymphoid cells), which include both myoid cells and thymic epithelial cells. All three cell types express various nAChRs. Expression of mRNAs encoding the neuron type alpha3, alpha5 and beta4 nAChR subunits (49-51, 57, 58), as well as the muscle type alpha1 subunit (59), has been detected in human thymus tissues and in cultured thymic epithelial cells. In addition, Kuo et al. (55) detected the expression of the alpha2, alpha3, alpha4, alpha5, alpha7, beta2 and beta4 subunits in cultured murine fetal thymic organ, and Navaneetham et al. (60) found expression of mRNAs encoding the muscle type alpha1, epsilon, beta1 and gamma nAChR subunits in all or most thymus tissue samples from 20 healthy subjects and 13 myasthenia gravis patients. The delta subunit mRNA was detectable in only 2 of the healthy subjects. Apparently, thymic stromal cells express not only neuron type but also muscle type nAChR subunits. One must therefore be cautious when interpreting data obtained from experiments using whole thymus tissue; under those conditions it is not presently possible to identify which thymic cell type expresses a given subunit.
ACh
The presence of ACh in blood has been a matter of controversy since the 1920s (for review, see Kawashima & Fujii (12) ). However, the development of a highly sensitive, specific and simple radioimmunoassay (RIA) for ACh by Kawashima et al. (61) has done much to resolve that question. Because this RIA can accommodate sample sizes of up to 400 microL and has a sensitivity of 3 pg (about 20 fmol)/tube, it can determine ACh concentrations as low as 7.5 pg/mL (62) . Using this RIA, considerable amounts of ACh has been detected in the blood and plasma of various mammalian species (Table 5) (63) (64) (65) (66) (67) (68) : cattle have the highest blood ACh content; the ACh content of human blood is comparable to that of chimpanzee, pig and rabbit. It is noteworthy that there is considerable variation in blood ACh among human subjects, but it does not vary within a given subject (65) . The physiological significance of high blood ACh content is not yet known.
Because of the high AChE and ChE activities in blood, the presence of ACh in lymphocytes had, until recently, been beyond imagination for most of us. Using the aforementioned RIA, Kajiyama et al. (69, 70) and Kawashima et al. (65) detected, for the first time, the localization of ACh in rabbit buffy coat cells and in human circulating MNLs. In humans, about 60% of blood ACh is localized in MNLs, suggesting that blood ACh originates mainly from lymphocytes. A considerable amount of ACh has also been detected in cells from human leukemic T cell lines, but not in cells from human leukemic B cell lines (71, 72) (Table 6) 
ChAT
Using the Fonnum method (76), Kajiyama et al. (69, 70) demonstrated the presence of both AChsynthesizing activity and ACh in rabbit buffy coat cells and in human peripheral blood MNLs, which consisted mainly of lymphocytes. Rinner et al. (77) also detected AChsynthesizing activity in lymphocytes from rat thymus, spleen and blood, and in mouse and human lymphoid cell lines.
ChAT expression in human lymphocytes
Fujii et al. ChAT mRNA was confirmed in human MNLs (79), rat lymphocytes (73) and other human leukemic T cell lines (72) (see Table 6 ). When ACh-synthesizing activity was determined by the Fonnum method (76), both CarAT and ChAT were found to contribute to the synthesis of ACh from choline and AcCoA. With that method, therefore, it is advisable to use specific inhibitors of ChAT and CarAT (e.g., bromoACh and bromoacetylcarnitine, respectively) to ascribe the ACh-synthesizing activity to either of the two enzymes (7, 8, 81). In human T and B cell lines, Fujii et al. (72) detected varying levels of CarAT activity, but no correlation was observed between ACh content and CarAT activity (see Table 6 
ChAT mRNA molecular species expressed in lymphocytes
Expression of five distinct ChAT mRNA species (R-, N0-, N1-, N2-and M-type), which likely differ with respect to translation efficiency and stability, has been detected in human cholinergic neurons (82). MOLT-3 human leukemic T cells express only N2-type mRNA, while CEM cells express N2-, M-and, to a lesser extent, N1-type mRNA (83). PHA significantly increases expression of N2-type mRNA in MOLT-3 cells and induces low levels of N0-type mRNA expression in CEM cells (83). The PHA stimulation increases cellular ACh content and release in MOLT-3 cells, but not CEM cells (71) suggests that the level of N2-type mRNA is a key determinant of lymphocytic ChAT activity and ACh content (see Table 6 ). No R-type mRNA is expressed in either MOLT-3 or CEM cells. The relation between the inability of lymphocytes to express R-type mRNA and their low capacity to synthesize ACh, as compared to cholinergic neurons, remains to be clarified.
Expression of ChAT mRNA in thymic epithelial cells
The presence of ACh-synthesizing activity in thymocytes was first reported by Rinner et al. (77) , and Mihovilovic and Butterworth-Robinette (58) recently detected expression of ChAT mRNA in the TE750 thymic epithelial cell line. Together, these findings suggest the possibility that ACh is synthesized not only by thymocytes but also by thymic epithelial cells, and that ACh released from these cells plays a role in the regulation of maturation, selection and differentiation of T cells during the interaction of immature T cells with thymic epithelial cells (see section 5.2).
VAChT
In the cholinergic neurons, the VAChT gene is located within the first intron of the ChAT gene (9, 84-87), and expression of VAChT is co-regulated with that of ChAT (10, 88-91). Using human MNLs, Fujii et al. (79) attempted to determine whether VAChT gene expression is induced along with ChAT when T cells are immunologically stimulated with PHA. They found that whereas PHA up-regulated expression of ChAT mRNA and potentiated ACh-synthesizing activity and ACh synthesis, there was no expression of VAChT mRNA in PHA-stimulated MNLs. On the other hand, Tayebati et al. (37) detected VAChT immunoreactivity in human peripheral blood T and B cells. Although no structures resembling synaptic vesicles have ever been observed histologically in lymphocytes, the possibility that ACh in T cells is localized within a storage apparatus cannot be ruled out; that nicotine causes an increase in plasma ACh and a decrease of the ACh content of blood cells in rabbits suggests release of ACh from blood cells to plasma via a depolarization-dependent pathways (64) . On the other hand, it may be that ACh in T cells is synthesized when necessary and then directly released without storage. Further studies will be needed to confirm the role, if any, of VAChT and ACh storage vesicles in lymphocytes.
CHT1
It is generally accepted that choline taken up by the CHT1 is utilized exclusively for ACh synthesis, and that choline uptake by the CHT1 is the rate-limiting step in ACh synthesis catalyzed by ChAT in cholinergic neurons (8 (Fujii et al., in preparation) . Collectively, these results provide molecular biological, pharmacological and immunocytochemical evidence that MOLT-3 cells express CHT1, and suggest that CHT1 plays a key role in mediating uptake of choline into T cells for ACh synthesis. Still, we cannot rule out the possibility that choline from other sources is also used for ACh synthesis in T cells.
AChE
The mechanisms involved in the termination of ACh action are quite different from those of other neurotransmitters. Whereas, catecholamines and serotonin are removed from their target sites mainly by a reuptake mechanism via respective transporters, the action of ACh is terminated exclusively by rapid hydrolysis into choline and acetate by AChE at neuromuscular and neuroeffector junctions, and by ChE in plasma, liver and neuronal elements. It is now generally accepted that AChE is expressed not only in cholinergic neurons, but also in other neurons and in non-neural tissues, irrespective of direct cholinergic innervations (e.g., Bellinger et al. 
ROLES OF AChRs IN THE REGULATION OF LYMPHOCYTE FUNCTION
The lymphocytic cholinergic system operates through ACh released from T cells acting as an autocrine and/or paracrine factor on either mAChRs or nAChRs on ] i (see Table 1 ). Most of these responses support the idea that the lymphocytic cholinergic system is involved in the regulation of lymphocyte function, acting via mAChRs coupled to PLC or adenylyl cyclase and nAChRs forming ligand-gated ion channels. Table 1 ), are in some way related to that up-regulation of c-fos expression.
Stimulation of lymphocytic nitric oxide (NO) synthesis by mAChR agonists
NO synthase (NOS) catalyzes the synthesis of NO from L-arginine. Human lymphocytes and leukemic cell lines express the endothelial, neuronal and inducible (ecNOS, nNOS and iNOS, respectively) forms of NOS mRNA and protein, and exhibit NOS activity (for review see Kawashima and Fujii (12) ). Using quantitative fluorescence microscopy and a novel NO-sensitive fluorescent indicator, DAF-2 (104), Kamimura et al. (105) demonstrated that Oxo-M enhances NO production in CEM cells expressing mRNAs encoding iNOS and nNOS and the M 1 , M 3 , M 4 and M 5 mAChRs (Table 3 ). The effect of Oxo-M on NO production was inhibited by N G -nitro-L-arginine methyl ester, a NOS inhibitor, and by the mAChR antagonists 4-DAMP, pirenzepine and atropine, which suggests that ACh stimulates NO synthesis by nNOS and/or iNOS in lymphocytes via PLC-coupled M 1 , M 3 and/or M 5 mAChR-mediated pathways. This means that the enhanced cytotoxicity and increased cGMP synthesis observed in lymphocytes after mAChR stimulation (see Table 1 ) are likely related, at least in part, to increased NO production.
Enhancement of interleukin (IL)-2-mediated signal transduction
Fujino et al. Most available data on the effects of mAChR stimulation in lymphocytes and its targets have been derived from acute in vitro studies (see reviews by Kawashima and Fujii (12-14); Fujii and Kawashima (11); Maslinski (108)). However, observations of the in vivo effects of long-term stimulation or inhibition of mAChRs on lymphocytes will be needed if we are to relate lymphocytic cholinergic activity to the regulation of immune function.
nAChRs
With a special emphasis on the effects of smoking on immune function, the roles of nAChRs in the regulation of lymphocyte activity has been investigated both in vitro and in vivo (12, 13). ] i transients elicited by either nicotine or epibatidine, an alpha3 alpha4, and alpha7 subunit agonist, in CEM cells expressing mRNAs for the alpha3, alpha5, alpha6 and alpha7 nAChR subunits were effectively suppressed by alpha-BTX, which indicates that the alpha7 nAChR is at least partly responsible for nicotine-induced Ca 2+ signaling in lymphocytes. The physiological significance of such Ca 2+ signaling in lymphocytes is not known, however.
Effects of nAChR agonists on [
Middlebrook et al. (110) suggested that nAChRs were involved in the regulation of thymocyte development based on their observation that continuously exposing isolated fetal murine thymus to nicotine increased the numbers of immature T cells while diminishing numbers of mature T cells. Using RT-PCR techniques, Kimura et al. (103) found that long-term (1-8 weeks) exposure to nicotine (0.01-10 microM) in CEM cells down-regulates expression of alpha7 and other nAChR alpha subunits. Moreover, Ca 2+ signaling evoked by nicotine declined significantly as the duration of nicotine exposure became more prolonged. These findings suggest that nicotine, and most likely smoking, affects immune function by suppressing expression of nAChR subunits involved in Ca 2+ signaling in lymphocytes.
Effects of systemic nicotine administration on lymphocyte function
Singh et al. (111) suggested that T cell proliferation is regulated via nAChR-mediated pathways based on their observations that acute or chronic administration of nicotine inhibited concanavalin Ainduced MNL proliferation in rats, and that the effect was reversed by mecamylamine, a nAChR antagonist. Most other data obtained in vivo also suggest that continuously exposing T cells to nicotine suppresses immune function by inhibiting proliferative responses (111, 112) , or by causing anergy through constitutive activation of protein kinases and depletion of IP 3 -sensitive Ca 2+ stores (113) (114) (115) . However, these investigators also found that acute nicotine administration increased plasma cortisone levels; that the effect on plasma cortisone was inhibited by mecamylamine; and that the acute effects of nicotine on T cell proliferative responses were abolished in adrenalectomized animals. These findings highlight the importance of bearing in mind the hormonal effects of acutely administered nicotine. Still, they clearly support the idea that ACh and nicotine, perhaps incorporated through smoking, modulate immune function by affecting lymphocyte proliferation.
REGULATION OF LYMPHOCYTIC CHOLINERGIC ACTIVITY
Through various cell surface molecules, including cell adhesion molecules (CAMs), lymphocytes can interact directly with targets expressing the respective counter molecules. So far, several cell surface molecules have been shown to be involved in regulating lymphocytic cholinergic activity (13, 14, 80, 116, 117) . For example, stimulating T or B cells with their respective activators via cell surface molecules -e.g., T cell receptor (TCR)/CD3 complexes, CD2, CD7 and CD11a on T cells and surface immunoglobulin on B cells -up-regulates ChAT and M 5 mAChR gene expression (71, 73, 79, 80, 116, 117) . And activation of G s proteincoupled EP 4 receptor with prostaglandin E 2 (PGE 2 ) enhances ACh synthesis (118), while apelin acts via the G i protein-coupled orphan receptor APJ to suppress ACh synthesis in MOLT-3 cells (119). It thus appears that both immunological and inflammatory processes, and a variety of biologically active substances, are involved in regulating lymphocytic cholinergic activity. The effects of cytokines and chemokines on lymphocytic cholinergic activity remain to be investigated.
Cell surface molecules 5.1.1. TCR/CD3 complexes on T cells
PHA activates T cells by binding to TCR/CD3 complexes, which leads to activation of the PLC-IP 3 system (120) and, in turn, activation of protein kinase C (PKC) and/or mitogen-activated protein kinase (MAPK) cascades. 
CD2, CD7 and CD11a on T cells
Antithymocyte globulin-Fresenius (ATG-F), which is comprised of rabbit globulin against human thymocytes, is used as an immunosuppressive after renal allograft (121) and after hematopoietic stem cell transplantation (122) carried out in the treatment of aplastic anemia (123, 124) . ATG-F acts via the CD2, CD7 and CD11a cell surface molecules (122) , also known as lymphocyte function-associated antigen 2 (LFA-2), an immunoglobulin superfamily member and LFA-1 alphachain, respectively. Stimulation of these molecules with respective mAbs activates intracellular signaling pathways leading to increases in [Ca 2+ ] i and modulation of lymphocyte function (125, 126).
Fujii et al. (116) found that incubating CEM cells with ATG-F enhances ACh release from the cells within 6 h, which initially led to declines in intracellular ACh content. However, the ACh content of the cells recovered within 48 h as a result of up-regulation of ChAT expression. ATG-F also induced rapid, transient increases in [Ca 2+ ] i , and similar effects were elicited by anti-CD7 mAb, which is consistent with observations made by Ledbetter et al. (125) and Leta et al. (126) in other cell types and suggests that the increase in ACh release observed during the early stages of the experiments was due to increases in [Ca 2+ ] i induced by ATG-F via its interaction with CD7. On the other hand, incubation for 48 h with anti-CD11a mAb up-regulated the expression of ChAT mRNA in CEM cells, suggesting ATG-F stimulates ACh synthesis via its interaction with CD11a. ATG-F also up-regulated expression of M 5 mAChR mRNA (116) . It thus appears that in T cells surface molecules involved in cell-to-cell adhesion and/or aggregation are involved in regulating lymphocytic cholinergic activity by enhancing synthesis and release of ACh and expression of M 5 mAChR.
Surface immunoglobulin on B cells
Staphylococcus aureus Cowan I (SAC), a B cell activator, initiates a signal transduction cascade involving tyrosine kinase-mediated activation of PLC, which in turn activates PKC and promotes B cell proliferation by binding to surface immunoglobulin. SAC up-regulates M 5 mAChR mRNA expression in Daudi human leukemic B cells, but has no effect on M 3 or M 4 mAChR mRNA expression (117) . PMA together with ionomycin also up-regulates M 5 mAChR expression in Daudi cells, suggesting that, as in T cells, PKC is involved in stimulus-evoked up-regulation of M 5 mAChR expression in B cells. 
Biologically active substances
So far, among the vast number of biologically active substances known, only PGE 2 and apelin have been investigated with respect to their capacity to affect lymphocytic cholinergic activity.
PGE 2
Within the immune system, PGE 2 is synthesized mainly by antigen presenting cells, such as macrophages and monocytes (127) (128) (129) . PGE 2 inhibits T cell proliferation induced by activators, such as PHA, concanavalin A and antibodies against CD3 (130) (131) (132) , suggesting it contributes to the regulation of immune function by modulating the activities of T cells.
Suenaga et al. (118) tested whether ONO-4819, a selective EP 4 receptor agonist, has any ability to modulate lymphocytic cholinergic activity in MOLT-3 cells, which express all four EP receptors (EP 1 -EP 4 ). They found that PHA significantly enhanced expression of EP 4 receptor mRNA during the first 3-6 h of exposure. ONO-4819 added to cultures after 3 h of PHA stimulation significantly increased cellular ACh content and release, and upregulated expression of ChAT mRNA and ChAT activity, but inhibited MOLT-3 cell proliferation. This suggests that PGE 2 released from antigen presenting cells during their interaction with T cells facilitates lymphocytic cholinergic transmission, at least in part through EP 4 receptor-mediated pathways. At present, however, it remains unclear whether the inhibitory effect of PGE 2 on T cell proliferation is mediated directly or indirectly through the enhanced lymphocytic cholinergic transmission.
Apelin
The orphan receptor APJ is coupled to G i protein, which inhibits adenylyl cyclase activity (133) . Its endogenous ligand is apelin, whose cDNA has been isolated from human, bovine, rat and mouse (133) (134) (135) . In vivo, apelin is synthesized as a 77-amino acid preprotein and then cleaved to yield the mature protein comprised of the 36 C-terminal amino acids (apelin-36) (134) . Apelin mRNA has been identified in a number of rat tissues, in particular mammary gland during pregnancy and lactation (134) . Large amounts of apelin are secreted in bovine colostrum, and it even remains detectable in commercial bovine milk. In mouse spleen cells, apelin partially suppresses cytokine production induced via TCR/CD3-mediated pathways, suggesting apelin modulates immune function in neonates (134) .
Horiuchi et al. (119) investigated whether apelin is involved in the regulation of lymphocytic cholinergic activity using various human leukemic T and B cell lines as models. APJ mRNA was constitutively expressed in T and B cell lines, among which MOLT-3 and Daudi cells respectively expressed the highest levels of APJ mRNA. Apelin-13, a 13-amino acid synthetic C-terminal peptide that is more active than native apelin-36 (133), upregulated expression of APJ mRNA in PHA-stimulated MOLT-3 cells, whereas it down-regulated expression of ChAT and interleukin-2 mRNAs ( Figure 5 ). This suggests that apelin down-regulates lymphocytic cholinergic activity during immunological responses by inhibiting cAMP production via activation of the G i -coupled orphan receptor APJ, which is consistent with the finding that cAMP upregulates ChAT induction (136).
POSSIBLE PHYSIOLOGICAL FUNCTIONS OF THE LYMPHOCYTIC CHOLINERGIC SYSTEM

Antigen presentation
T cells interact with antigen presenting cells expressing major histocompatibility complex (MHC) class II or MHC class I via the TCR/CD3 complex plus CD4 or CD8, respectively. On the basis of the findings discussed above, it seems likely that antigen presentation activates lymphocytic cholinergic activity by enhancing synthesis and release of ACh and expression of M 5 mAChR. To test this idea, Watanabe et al. (137) (Figure 6 ). Furthermore, because of the close proximity of T cells and antigen presenting cells under these conditions, even a small amount of ACh released from an activated T cell into the microenvironment should be able to interact with AChRs on the target cells before hydrolysis by AChE.
Interaction of T cells with thymic stromal cells
As mentioned above, the thymus is comprised of thymocytes (lymphoid cells) and myoid and epithelial cells (non-lymphoid cells). Interactions between developing thymocytes and thymic epithelial cells are necessary for maturation of thymocytes into mature T cells, and these interactions are all mediated by CAMs on immature T cells that bind to various molecules expressed on the surface of thymic epithelial cells. Patel et al. (138, 139) demonstrated that thymic epithelial cells express various CAMs, cytokine receptors, Apo-1, and MHC-encoded molecules. Activation of thymic epithelial cells by IFN-gamma induces marked increases of the expression of surface molecules such as CD54 (intercellular adhesion molecule-1 (ICAM-1)), which interacts with LFA-1, and MHC class I and MHC class II, which interact with CD8 and CD4, respectively. Since both thymic epithelial cells (58) and thymocytes (73) not only synthesize ACh but also express various nAChR subunits (see sections 3.1.2 and 3.1.3), it seems likely that ACh released from thymic epithelial cells and/or thymocytes plays a role in regulating differentiation, maturation and selection of T cells, acting in autocrine and/or paracrine fashion via nAChRs (58, 140) (Figure 7 ). While observations on the effects of nicotine on T cell maturation support this hypothesis (110) , it is yet to be confirmed.
Several lines of evidence support the idea of postsynaptic sympathetic innervations of the thymus (95, [141] [142] [143] [144] [145] . On the other hand, it is controversial whether there is direct cholinergic innervations of thymic epithelial cells or thymocytes. On the basis of histochemical staining and immunocytochemical labeling with anti-ChAT mAb, Fatani et al. (146) reported that there is cholinergic innervations along the blood vessels within the thymic traveculae and the parenchyma, while others have also detected AChE-positive fibers and cells (144, (147) (148) (149) . Nevertheless, microscopic dissection of the terminal branches of the vagus nerve by Nance et al. (95) failed to identify any major branches leading to the thymus, making direct vagal innervations of the thymus unlikely. Moreover, unilateral vagotomy did not alter ChE activity in the thymus. At present, no conclusive evidence for or against direct cholinergic innervations of thymic epithelial cells and thymocytes is available. However, considering the extreme susceptibility of ACh to hydrolysis by AChE and ChE, as well as its physicochemical instability in physiological fluids (see reviews by Kawashima and Fujii (12, 13)), it seems highly unlikely that ACh released from cholinergic nerve endings would interact with receptors expressed on thymocytes.
Electrical stimulation of the vagal fibers running in the recurrent laryngeal nerve has a tonic and phasic facilitatory effect on the mechanism responsible for lymphocytic release from the thymus, which is modulated via nAChRs (150) . Since thymus tissue expresses both muscle type (59, 60) and neuron type nAChR subunits (51, 55), it may be that ACh released from vagal fibers directly innervating myoid cells induces contraction of the thymus by acting on muscle type nAChRs, thereby facilitating release of lymphocytes.
Autonomic innervations of the spleen appear to be relatively sparse. Nevertheless, direct contacts between noradrenergic sympathetic fibers and lymphocytes, as well as with other cells of the immune system, have been reported in the rat spleen (151) . Cholinergic innervations of the rat spleen is less likely, as AChE-positive staining colocalized with norepinephrine in noradrenergic nerves and persisted even after vagal denervation (94). . Schematic drawing illustrating the roles of lymphocyte cholinergic system in antigen presentation. ACh, acetylcholine; AChE, acetylcholinesterase; AcCoA, acetyl coenzyme A; APC, antigen presenting cell; ChAT, choline acetyltransferase; CHT1, high-affinity choline transporter; DAG, diacylglycerol; ER, endoplasmic reticulum; ICAM-1, intercellular adhesion molecule-1; IP 3 , inositol-1,4,5-trisphosphate; LFA-1, leukocyte function-associated antigen-1; mAChR, muscarinic ACh receptor; MAPK, mitogen activated protein kinase; MAPKK, MAP kinase kinase; MHC II, major histocompatibility complex class II; TCR, T cell receptor.
Interaction of T cells with vascular endothelial cells
T cells express various CAMs through which they interact with vascular endothelial cells; these include very late antigen-4 (VLA-4), a major adhesion receptor that interacts with vascular CAM-1 (VCAM-1); CD4, which interacts with MHC class II; LFA-1, which interacts with ICAM-1; and CD2, which interacts with LFA-3 (152, 153). Kokura et al. (153) found that interactions between T cells and postanoxic endothelial cells via VLA-4-/VCAM-1 potentiated the synthesis of tumor necrosis factor-alpha (TNF-alpha), leading to enhanced endothelial CAM expression.
Both T cells and vascular endothelial cells have the ability to synthesize ACh (see sections 3.2 and 3.3) (23-26) and to express mAChRs (see Table 3 ; Kan et al. (154) and Elhusseiny et al. (155)); expression of nAChRs has been confirmed in T cells (see Table 4 ), and is suggested in vascular endothelial cells (156) . This suggests that CAMmediated interactions between T cells and endothelial cells facilitate ACh synthesis and release in both cell types (Figure 8) . During CAM-mediated interactions, T cells and vascular endothelial cells may therefore communicate reciprocally via ACh, which stimulates mAChRs on both T cells and vascular endothelial cells, and possibly nAChRs on T cells. The fact that mAChR stimulation potentiates NO synthesis in both T cells and vascular endothelial cells (105, 157) suggests the possibility that potentiation of NO synthesis during the interaction evokes local vascular smooth muscle relaxation, thereby facilitating extravascular migration of T cells. We further suggest that ACh released from T cells, and possibly from vascular endothelial cells, plays a role in regulating production of TNF-alpha, which in turn acts on nAChRs in T cells.
Synthesis of TNF in inflammatory cells (e.g., macrophages) appears to be regulated, at least in part, via nAChR-mediated pathways (158, 159) . TNF concentrations in the conditioned medium of lipopolysaccharide (LPS)-stimulated macrophages were suppressed in the presence of either ACh or nicotine, and that suppression was reversed by addition of alpha-conotoxin, an inhibitor of alpha-BTXsensitive nAChRs. On the basis of their observation that electrical stimulation of the efferent vagus nerve suppressed serum TNF concentrations, which protected rats 
LYMPHOCYTIC CHOLINERGIC ACTIVITY IN ANIMAL MODELS WITH IMMUNE ABNORMALITIES
Using the spontaneously hypertensive rat (SHR), an immune deficiency model (for review see Takeichi (160)), and the MRL/MpJ-lpr/lpr (MRL-lpr) mouse, an immune accelerated model (161, 162), Fujimoto et al. (163, 164) obtained evidence to suggest that changes in lymphocytic cholinergic activity are related to immune dysfunction.
SHR
The SHR is a well-established hypertension model derived from the Wistar Kyoto rat (WKY) (165) and is also known to exhibit immune deficiencies resulting from the emergence of a natural thymocytotoxic autoantibody, an age-related decline of T cell function to various stimuli, and morphological changes in the thymus and spleen (160) . Fujimoto et al. (163) discovered that the ACh contents of the blood, MNLs, thymus and spleen in 5-to 20-week-old SHRs are all significantly lower than in age-matched WKYs, as is expression of ChAT mRNA in circulating MNLs, making it likely that the suppressed lymphocytic cholinergic activity reflects an immune deficiency related to T cell dysfunction.
MRL-lpr mice
The MRL-lpr mouse spontaneously develops a lupus-like autoimmune syndrome, the symptoms of which include nephritis due to production of antinuclear antibodies associated with massive lymphadenopathy related to expansion of a unique T cell subset expressing Thy-1, CD3 and B220 (161, 162) .
Fujimoto et al. (164) found that the ACh contents of the blood, thymus and spleen of 20-week-old MRL-lpr mice were significantly greater than in age-matched MPL/MpJ-+/+ (wild type) and BALB/c (control) mice, although no changes in lymphocytic cholinergic activity were detected at 5 and 10 weeks, when an autoimmune syndrome was yet not evident.
CONCLUSIONS AND PERSPECTIVES
It is now evident that lymphocytes express the components needed to constitute an independent, nonneuronal cholinergic system, and that lymphocytic cholinergic activity is regulated, at least in part, by immunological responses and is therefore a reflection of immune function. Still, the precise function and physiological significance of the lymphocytic cholinergic system remain unknown. Particularly important in the future will be in vivo studies of the roles of lymphocytic cholinergic system in the regulation of cytokine, chemokine and antibody production. The results of those studies should provide us with important clues about immune regulatory mechanisms and contribute to the development of new drugs with novel mechanisms of action with which to modulate immune function.
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